AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting real-world and clinical trial data for its gastroenterology drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in treating Crohn's disease and ulcerative colitis. The data demonstrated sustained symptom relief, improved quality of life, and lower hospitalization rates, reinforcing the drugs' efficacy, safety, and durability. Notably, risankizumab showed low treatment switch rates, and upadacitinib reduced hospitalizations compared to biologic dose escalation. These findings support AbbVie's leadership in advancing inflammatory bowel disease care and may influence future treatment guidelines and approvals.
US stock futures point to a strong start with Dow Jones up 1.1%, S&P 500 up 0.9%, and Nasdaq up 1.5%, driven by a sharp 6.3% drop in oil prices following a pause in US-Iran military actions. Although no official ceasefire is declared, Iran has agreed...
AbbVie has earned a buy rating due to accelerating revenue and profit growth, supported by a reasonable valuation at 18 times forward P/E. The company offers a 2.7% forward dividend yield, outperforming its peers by 68%, and has maintained 12 consecu...
Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a bispecific antibody treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in ...
